

Glaucocalyxin A Datasheet

4th Edition (Revised in July, 2016)

[Product Information]

Name: Glaucocalyxin A

Catalog No.: CFN90207

Cas No.: 79498-31-0

Purity: >=98%


M.F: C₂₀H₂₈O₄

M.W: 332.43

Physical Description: White powder

Synonyms: (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione;

Leukamenin F.



[Intended Use]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

[Source]

The herbs of *Rabdosia rubescens*.

[Biological Activity or Inhibitors]

Glucocalyxin A can induce apoptosis in HL-60 cells through ROS-dependent mitochondrial dysfunction pathway.^[1]

Glucocalyxin-A has regulation of microglia activity, can attenuate lipopolysaccharide-stimulated neuroinflammation through NF- κ B and p38 MAPK signaling pathways.^[2]

Glucocalyxin A has inhibition of platelet aggregation, it can inhibit ADP- or arachidonic acid-induced platelet aggregation with IC₅₀ values of 4.4 μ mol/l, 14.1 μ mol/l respectively; it also can inhibit PAF-induced aggregation of rabbit platelets which were refractory to ADP and arachidonic acid with an IC₅₀ value of 13.7 μ mol/l. ^[3]

Glucocalyxin A pretreatment can protect H9c2 cells from H₂O₂-induced injury and markedly improved cell viability.^[4]

Glucocalyxin A is a negative Akt regulator, can specifically induce apoptosis in human brain glioblastoma U87MG cells.^[5]

Glucocalyxin A can effectively ameliorate pulmonary fibrosis through the antagonism of leukocyte infiltration and proinflammatory cytokine production, suggesting that it may become a potential anti-fibrotic agent in Idiopathic pulmonary fibrosis (IPF) management.^[6]

[Solvent]

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

[HPLC Method]^[7]

Mobile phase: Acetonitrile-Methanol-H₂O, gradient elution ;

Flow rate: 1.0 ml/min;

Column temperature: 30 °C;

The wave length of determination: 232 nm.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

- [1] Li W G, Jian Z, Wen H Y, et al. *Toxicol. in Vitro An International Journal Published in Association with Bibra*, 2011, 25(1):51-63.
- [2] Kim B W, Koppula S, Hong S S, et al. *Plos One*, 2013, 8(2):e55792-e55792.
- [3] Bin Z, Kun L. *Thromb. Haemostasis*, 1992, 67(4):458-60.
- [4] Liu M J, Sun Q, Yu L J, et al. *Lat. Am. J. Pharm.* 2014, 33(7):1216-20.
- [5] Xiao X, Cao W, Jiang X, et al. *Acta Bioch. Bioph. Sin.*, 2013, 45(11):946-52.
- [6] Yang F, Cao Y, Zhang J, et al. *Biochem. Biophys. Res. Commun.*, 2016.11.003.
- [7] Jiang H L, Ming Z, Yong C, et al. *Chinese Traditional Patent Medicine*, 2013, 35(1):86-9.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,
Wuhan Economic and Technological Development Zone,
Wuhan, Hubei 430056,
China

Email: info@chemfaces.com

Tel: +86-27-84237783

Fax: +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com